Pure Global

TOTAL PROTEIN Biuret Method - India CDSCO Medical Device Registration

TOTAL PROTEIN Biuret Method is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2023/000051_d3078f4ba6210b08f463aed013adb44f_23639a4be0cc40cfe7a2dd909db4746f. This device is marketed under the brand name BIOLABO ACID CALCIUM Arsenazo III Method. The license holder is Wheecon Instruments Private Limited, and it is classified as Device Class Class B. The approving authority is CDSCO.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
CDSCO Registered
Class Class B
TOTAL PROTEIN Biuret Method
UID: IMP/IVD/2023/000051_d3078f4ba6210b08f463aed013adb44f_23639a4be0cc40cfe7a2dd909db4746f

Brand Name

BIOLABO ACID CALCIUM Arsenazo III Method

Device Class

Class B

Approving Authority

CDSCO

Product Information

The overall composition of a patientโ€™s plasma or serum should be studied first by determining its total protein content and then its composition by electrophoresis. Decrease in the volume of plasma water (BIOLABO ACID CALCIUM Arsenazo III Method), noted in dehydratation (BIOLABO ACID CALCIUM Arsenazo III Method), is reflected as relative hyperproteinemia. Hemodilution (BIOLABO ACID CALCIUM Arsenazo III Method) occuring with water intoxication or salt retention syndromes, during massive intravenous infusions, and physiologically when a recombant position is assumed, is reflected as relative hypoproteinemia. Hypoproteinemia due to low levels of albumine in plasma is also common and has many causes. Mild hyperproteinemia may be caused by an increased in the concentration of specific proteins (BIOLABO ACID CALCIUM Arsenazo III Method). Marked hyperproteinemia may be caused by high levels of monoclonal immunoglobulins produced in multiple myelomia and other malignant paraproteinemias

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing